Search alternatives:
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
site decrease » sizes decrease (Expand Search), step decrease (Expand Search), rate decreased (Expand Search)
a marked » _ marked (Expand Search), a market (Expand Search), _ market (Expand Search)
a marker » _ marker (Expand Search), _ markers (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), b large (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
site decrease » sizes decrease (Expand Search), step decrease (Expand Search), rate decreased (Expand Search)
a marked » _ marked (Expand Search), a market (Expand Search), _ market (Expand Search)
a marker » _ marker (Expand Search), _ markers (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), b large (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
Relationship between the Gender Representation Disparity Index (GRDI) and average explicit sex markers in film criticism, illustrating a decrease in markers as the GRDI moves toward a female-dominated cast.
Published 2025“…<p>Relationship between the Gender Representation Disparity Index (GRDI) and average explicit sex markers in film criticism, illustrating a decrease in markers as the GRDI moves toward a female-dominated cast.…”
-
8
Table 1_Demethylase FTO mediates m6A modification of ENST00000619282 to promote apoptosis escape in rheumatoid arthritis and the intervention effect of Xinfeng Capsule.docx
Published 2025“…Bioinformatics prediction, MeRIP-qPCR, RIP, and RNA pull-down assays were employed to identify the m6A modification sites of ENST00000619282 and their interactions with FTO/YTHDF1. …”
-
9
-
10
-
11
The m6A reader YTHDF2 protects vascular smooth muscle cells against the osteogenic differentiation through targeting Runx2
Published 2025“…These results suggest that YTHDF2 directly binds to the m6A modification site of Runx2 to mediate the mRNA degradation that prevents VC by inhibiting the osteogenic development of VSMCs. …”
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …”